scholarly journals Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia

2016 ◽  
Author(s):  
Y Schmiedel ◽  
S Zimmerli
Keyword(s):  
Invasive Candidiasis ◽  
Pneumocystis Pneumonia ◽  
Fungal Diseases ◽  
Invasive Fungal Diseases

scholarly journals Performance of Existing Definitions and Tests for the Diagnosis of Invasive Fungal Diseases other than Invasive Candidiasis and Invasive Aspergillosis in Critically Ill, Adult Patients: A Systematic Review with Qualitative Evidence Synthesis

2021 ◽  
Vol 7 (3) ◽  
pp. 176
Author(s):  
Daniele Giacobbe ◽  
Andrea Cortegiani ◽  
Ilias Karaiskos ◽  
Toine Mercier ◽  
Sofia Tejada ◽  
...  
Keyword(s):  
At Risk ◽  
Invasive Aspergillosis ◽  
Critically Ill ◽  
Systematic Reviews ◽  
Invasive Candidiasis ◽  
Fungal Diseases ◽  
Adult Patients ◽  
Qualitative Evidence Synthesis ◽  
Invasive Fungal Diseases ◽  
Populations At Risk

The Fungal Infections Definitions in Intensive Care Unit (ICU) patients (FUNDICU) project aims to provide standard sets of definitions for invasive fungal diseases (IFDs) in critically ill, adult patients, including invasive aspergillosis (IA), invasive candidiasis (IC), Pneumocystis jirovecii pneumonia (PJP), and other non-IA, non-IC IFDs. The first step of the project was the conduction of separated systematic reviews of the characteristics and applicability to critically ill, adult patients outside classical populations at risk (hematology patients, solid organ transplant recipients) of available definitions and diagnostic tests for IFDs. We report here the results of two systematic reviews exploring the performance of available definitions and tests, for PJP and for other non-IA, non-IC IFDs. Starting from 2585 and 4584 records for PJP and other IFDs, respectively, 89 and 61 studies were deemed as eligible for full-text evaluation. However, only two studies for PJP and no studies for other IFDs met the FUNDICU protocol criteria for inclusion in qualitative synthesis. Currently, there is no sufficient solid data for directly evaluating the performance of existing definitions and laboratory tests for the diagnosis of PJP and other non-IA, non-IC IFDs in critically ill adult patients outside classical populations at risk.

scholarly journals Prospective Evaluation of Serum β-Glucan Testing in Patients With Probable or Proven Fungal Diseases

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Cécile Angebault ◽  
Fanny Lanternier ◽  
Frédéric Dalle ◽  
Cécile Schrimpf ◽  
Anne-Laure Roupie ◽  
...  
Keyword(s):  
Clinical Utility ◽  
Clinical Suspicion ◽  
Fungal Diseases ◽  
Prospective Evaluation ◽  
Invasive Fungal Diseases ◽  
Undetectable Serum ◽  
Antifungal Use ◽  
Kinetics Of ◽  
Rule Out

Abstract Background.  Early diagnosis and treatment are crucial in invasive fungal diseases (IFD). Serum (1-3)-β-d-glucan (BG) is believed to be an early IFD marker, but its diagnostic performance has been ambiguous, with insufficient data regarding sensitivity at the time of IFD diagnosis (TOD) and according to outcome. Whether its clinical utility is equivalent for all types of IFD remains unknown. Methods.  We included 143 patients with proven or probable IFD (49 invasive candidiasis, 45 invasive aspergillosis [IA], and 49 rare IFD) and analyzed serum BG (Fungitell) at TOD and during treatment. Results.  (1-3)-β-d-glucan was undetectable at TOD in 36% and 48% of patients with candidemia and IA, respectively; there was no correlation between negative BG results at TOD and patients' characteristics, localization of infection, or prior antifungal use. Nevertheless, patients with candidemia due to Candida albicans were more likely to test positive for BG at TOD (odds ratio = 25.4, P = .01) than patients infected with other Candida species. In 70% of the patients with a follow-up, BG negativation occurred in >1 month for candidemia and >3 months for IA. A slower BG decrease in patients with candidemia was associated with deep-seated localizations (P = .04). Thirty-nine percent of patients with rare IFD had undetectable BG at TOD; nonetheless, all patients with chronic subcutaneous IFD tested positive at TOD. Conclusions.  Undetectable serum BG does not rule out an early IFD, when the clinical suspicion is high. After IFD diagnostic, kinetics of serum BG are difficult to relate to clinical outcome.

scholarly journals Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart

2017 ◽  
Vol 10 (6) ◽  
Author(s):  
Ersilia M. DeFilippis ◽  
Sarah Cuddy ◽  
Carolyn Glass ◽  
Sarv Priya ◽  
Ayaz Aghayev ◽  
...  
Keyword(s):  
Multimodality Imaging ◽  
Fungal Diseases ◽  
Invasive Fungal Diseases

scholarly journals Editorial: Host and Pathogen Determinants of Allergic and Invasive Fungal Diseases

2020 ◽  
Vol 11 ◽  
Author(s):  
Joshua J. Obar ◽  
Agostinho Carvalho ◽  
Joana Vitte ◽  
Stéphane Ranque
Keyword(s):  
Fungal Diseases ◽  
Invasive Fungal Diseases
Sign in / Sign up

Export Citation Format

Share Document